仁济医院最新研究成果：新家族史评分系统可预测乳腺癌新辅助含铂化疗疗效 - 2021年09月08日

Local medical experts have developed a new theory for analyzing family history to predict possible breast cancer incidences. The new theory can be used to forecast the chemotherapy treatment outcomes as well.

The Neo-Family History Score, or NeoFHS, is a practical and effective biomarker for indicating the effects of platinum-based chemotherapy, and also for forecasting survival outcomes and chemotherapy-induced negative side effects. It can help screen treatment candidates' potential responses and guide safety management.

The discovery, developed by Dr Lu Jinsong from Renji Hospital and his team, was published in the world-leading journal The Lancet's EClinicalMedicine.